Stocks › C › CYCC

Cyclacel Pharmaceuticals, Inc. (CYCC) — Earnings Call X-Ray

Our AI read all 35 of CYCC's earnings calls (2016–2024) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q2 2024 · sign up to see
Previous Call Grade
D
Q1 2024
Expected Move
🔒
next 45 days · members
Calls Analyzed
35
2016–2024
Avg Candor
6.1/9
evasion 2.7/9
Critic AmmunitionUnderused Fixed CostsMargins ContractingReads RehearsedQuestion Left HangingResults Worse Than Direction

Call-by-call analysis

🔒 Q2 2024 earnings call 2024-08-14 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor ■/9
Specificity ■/9
Evasion ■/9
Stress ■/9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q2 2024 call grade is ready
The full 37-point AI read of CYCC's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

D Q1 2024 earnings call 2024-05-14

Management gave no formal guidance against contracting margins. The delivery was rich in specifics.

Margins: contractingCapex: decreasing 1 analysts · 2 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 7/9
Evasion 2/9
Confidence 6/9
Uncertainty 5/9
Promotion 5/9
Stress 3/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q4 2023 earnings call 2024-03-19

Management gave no formal guidance against contracting margins. The delivery was rich in specifics.

Margins: contracting 2 analysts · 3 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 7/9
Evasion 3/9
Confidence 6/9
Uncertainty 6/9
Promotion 5/9
Stress 5/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q3 2023 earnings call 2023-11-13

Management gave no formal guidance against contracting margins. The delivery was rich in specifics, promotional in tone.

Margins: contractingCapex: increasing 2 analysts · 5 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 7/9
Evasion 4/9
Confidence 7/9
Uncertainty 5/9
Promotion 7/9
Stress 3/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q2 2023 earnings call 2023-08-09

Management gave no formal guidance. The delivery was rich in specifics.

3 analysts · 8 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 7/9
Evasion 4/9
Confidence 7/9
Uncertainty 5/9
Promotion 6/9
Stress 4/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q1 2023 earnings call 2023-05-11

Management held guidance steady. The delivery was rich in specifics.

Guidance: maintained 2 analysts · 4 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 7/9
Evasion 3/9
Confidence 7/9
Uncertainty 5/9
Promotion 6/9
Stress 2/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

C+ Q4 2022 earnings call 2023-03-06

Management held guidance steady against contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedMargins: contractingCapex: increasing 4 analysts · 11 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsedDirection beats results
Candor 7/9
Specificity 7/9
Evasion 1/9
Confidence 7/9
Uncertainty 4/9
Promotion 6/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q3 2022 earnings call 2022-11-09

Management held guidance steady. The delivery was rich in specifics, relaxed under questioning, promotional in tone.

Guidance: maintained 3 analysts · 6 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsed
Candor 6/9
Specificity 7/9
Evasion 4/9
Confidence 8/9
Uncertainty 5/9
Promotion 8/9
Stress 1/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q2 2022 2022-08-10 D noneunclearcontracting 6/9 3/9
Q1 2022 2022-05-11 D noneunclearcontracting 6/9 2/9
Q4 2021 2022-03-28 C+ noneunclearcontracting 7/9 2/9
Q3 2021 2021-11-10 D maintainedunclearcontracting 6/9 2/9
Q2 2021 2021-08-11 D noneunclearcontracting 6/9 3/9
Q1 2021 2021-05-12 C noneunclearcontracting 6/9 2/9
Q4 2020 2021-02-25 F noneunclearcontracting 4/9 6/9
Q3 2020 2020-11-11 D maintainedunclearcontracting 6/9 4/9
Q2 2020 2020-08-12 D maintainedunclearunclear 6/9 3/9
Q1 2020 2020-05-12 D maintainedunclearunclear 6/9 3/9
Q4 2019 2020-02-26 D noneunclearcontracting 7/9 2/9
Q3 2019 2019-11-13 D noneunclearunclear 7/9 2/9
Q2 2019 2019-08-13 D maintainedunclearunclear 5/9 2/9
Q1 2019 2019-05-14 D maintainedunclearunclear 6/9 1/9
Q4 2018 2019-03-27 D noneunclearcontracting 6/9 3/9
Q3 2018 2018-11-12 B raisedunclearunclear 7/9 2/9
Q2 2018 2018-08-09 D noneunclearstable 7/9 2/9
Q1 2018 2018-05-14 D noneunclearcontracting 7/9 2/9
Q4 2017 2018-03-28 D maintainedunclearunclear 6/9 4/9
Q3 2017 2017-11-09 D maintainedunclearunclear 6/9 2/9
Q2 2017 2017-08-09 F noneunclearcontracting 5/9 4/9
Q1 2017 2017-05-11 D maintainedunclearcontracting 6/9 2/9
Q4 2016 2017-03-28 D maintainedunclearunclear 7/9 3/9
Q3 2016 2016-11-14 F noneunclearcontracting 5/9 3/9
Q2 2016 2016-08-10 D noneunclearstable 6/9 0/9
Q1 2016 2016-05-11 F noneunclearcontracting 6/9 4/9
Q4 2015 2016-03-24 D maintainedunclearcontracting 6/9 3/9

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAC · AAC Holdings'AACAY · AAC Technologies HoldingAACG · ATA Creativity GlobalAADI · Aadi Bioscience, Inc.AALBF · Aalberts N.V.AAOI · Applied Optoelectronics,

← CYBR   All “C” companies    CYD →

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.